Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Crickets.
Try doing more than 18 seconds of research. You might figure out why Malik was brought on board. He worked for Cenkos. Cenkos repeatedly got Woodford to invest in small biotech. Woodford invested in NWBO after Malik was on board. Malik got a massive number of shares as a reward. Imo.
I’m through with you today.
Pardon: I meant tranches not trenches. 🙂
I see, apparently you think massive trenches of money are thought of the day they are given. Malik worked for Cenkos prior to the deal (and way prior to his bonus) and prior to joining the board. Why is that important?
Financial Times
Neil Woodford
The longtime links between Neil Woodford and a City broking minnow
Cenkos Securities has often managed to secure backing from the former star stock picker
The relationship between Neil Woodford and Cenkos Securities has bemused rivals.
Cat Rutter Pooley, City Correspondent JUNE 27 2019
Print this page
For almost 15 years, a minnow of London’s broking world has had an impressive ability to secure investment from Neil Woodford, the once star stock picker whose flagship fund is now grappling with a flood of investor redemptions.
The relationship between Mr Woodford and Cenkos Securities, which has specialised in bringing some of the UK’s smallest public companies to market since it was founded in 2004, has bemused rivals and fed City chatter.
Half of Cenkos’s top-20 equity fundraisings by value since the start of 2014 — when Mr Woodford left Invesco and struck out on his own — were in stocks where Woodford Investment Management disclosed an interest, according to Bloomberg data.
Among the deals the two did together were the refinancing of AA and the £1.2bn reverse takeover of used car dealership BCA Marketplace, which was bought by a private equity group this week. Cenkos also brought to market less well known companies, including Woodford-backed biotechnology groups Verseon and Abzena.
Recommended
Neil Woodford
Woodford Patient Capital unveils plans to sell assets to reduce debt
“It was for a while almost a given that any deal from Cenkos, whether it fitted with Woodford’s fund or not, would come into consideration,” said one investment adviser.
In the view of a rival broker: “[Woodford] consistently took issues from [Cenkos] that he wouldn’t take from other people.”
Cenkos said that “contrary to speculation there is no special relationship with Neil Woodford” and that it has “a standard arms-length relationship with its fund management clients, Mr Woodford’s funds being just one of many.”
The Judge saw the document that defendants intended to request July 12 for the final pleadings. The Judge shortened that to June 14.
Hello? Anybody in there????
I see, apparently you think massive trenches of money are thought of the day they are provided.
I see, apparently you think massive trenches of money are thought of the day they are given. Malik worked for Cenkos prior to the deal and prior to joining the board. Why is that important?
Financial Times
Neil Woodford
The longtime links between Neil Woodford and a City broking minnow
Cenkos Securities has often managed to secure backing from the former star stock picker
The relationship between Neil Woodford and Cenkos Securities has bemused rivals.
Cat Rutter Pooley, City Correspondent JUNE 27 2019
Print this page
For almost 15 years, a minnow of London’s broking world has had an impressive ability to secure investment from Neil Woodford, the once star stock picker whose flagship fund is now grappling with a flood of investor redemptions.
The relationship between Mr Woodford and Cenkos Securities, which has specialised in bringing some of the UK’s smallest public companies to market since it was founded in 2004, has bemused rivals and fed City chatter.
Half of Cenkos’s top-20 equity fundraisings by value since the start of 2014 — when Mr Woodford left Invesco and struck out on his own — were in stocks where Woodford Investment Management disclosed an interest, according to Bloomberg data.
Among the deals the two did together were the refinancing of AA and the £1.2bn reverse takeover of used car dealership BCA Marketplace, which was bought by a private equity group this week. Cenkos also brought to market less well known companies, including Woodford-backed biotechnology groups Verseon and Abzena.
Recommended
Neil Woodford
Woodford Patient Capital unveils plans to sell assets to reduce debt
“It was for a while almost a given that any deal from Cenkos, whether it fitted with Woodford’s fund or not, would come into consideration,” said one investment adviser.
In the view of a rival broker: “[Woodford] consistently took issues from [Cenkos] that he wouldn’t take from other people.”
Cenkos said that “contrary to speculation there is no special relationship with Neil Woodford” and that it has “a standard arms-length relationship with its fund management clients, Mr Woodford’s funds being just one of many.”
Look again. defendants were asking to complete pleadings on July 12, but Judge ordered June 14.
Defendant asked MTD pleadings to be concluded by July 12, but Judge ordered pleadings must be concluded by June 14. Defendant’s reply limited to 10 pages. (Instead of 20 pages).
Defendant asked MTD pleadings to be concluded by July 12, but Judge ordered pleadings must be concluded by June 14. Defendant’s reply limited to 10 pages. (Instead of 20 pages)
It’s the safest oncology therapy they’ve ever reviewed. They’ve had it in the UK for compassionate treatment for a decade. The Advent facility was recently certified separately for clinical, compassionate and commercial manufacturing using DCVax-l as their example process, and Advent was recertified for HTA on the day NWBO submitted their maa. MHRA and NICE recently made major strides since Brexit in increasing their efficiency with national reviews, partly because their international recognition program reduced the case load for national reviews, and partly due to new priorities like proportionate review. We are literally in MHRA’s and NICE’s biggest efficiency improvement window in the current year. NWBO used two editors to prepare their MAA. They spent about a year preparing for maa review inspections by conducting mock inspections with prior UK regulators.
So yeah, there’s a chance it gets done a little early.
150 days are only used “if required.”
They need to get a decision out “by” day 150, not necessarily “on” day 150.
They’d gladly get this done faster than 150 days if they can.
“The assessment process will run in two phases totalling 150 days with an intervening clock-off period between phase I and phase II, if required”
“Based on the assessment, the MHRA will provide a decision on approvability of the product by day 150.”
You think patents aren’t important when NWBO receives them, but you think they are important when you and your syndicate incorrectly tried to argue NWBO has no substantial intellectual property protection. You are a hack to suggest a DCVax-Direct patent that goes out to June 2036 in India, a country of 1.4 billion people, is meaningless.
Your level of incuriosity of a DCVax-Direct patent granted out to June 2036 in a country of 1.4 billion people followed a couple days later by a Native Indian billionaire venture capitalist taking a board position with NWBO is par for the course.
They didn’t put him on the board because he is supposedly a beaten down investor.
Think about it. The last time that board expanded, it was to reward Dr. Malik for bringing Woodford on board. After the blow up with Woodford, the board didn’t expand for many years.
A couple days after we received the DCVax-Direct patent in India, Jerry retired and Pat took his place.
Not a coincidence, imo.
He’ll be at the next ASM or whatever upcoming shareholder meeting that might occur before then, imo.
They trust him. That’s not an inner circle easily welcomed into.
LP is better than CD.
Geniuth.
Don’t believe either of you would know, and not being on the “CHM Slate” can even be better than being on it, or better than being on it in a later month.
Anyway, it’s all speculation.
It’s already contemplated in part of NWBO’s patents and patent applications. It was also discussed here long ago.
Maybe you should have read the entire thread.
Yeah, I think these chess moves were planned out further in advance than people might think. Don’t forget, in addition to NWBO getting a DCVax-Direct patent (method B+** as DocL and I like to call it) in India out to June 2036, and in addition to Mr. Sarma joining the board two days later, India is, as far as I know, the only country practicing commercial Intratumoral dendritic therapy against cancer with an Indian Company, albeit with an (arguably) less ideal product and less internationally recognized scientific support, and less internationally recognized patent, the potential symbiosis of a M@A of some sort is possible, and in addition to that, India has a closed system blood collection, leukapheresis transport system company that NWBO utilized, and probably still does. Can’t remember the name right now.
** Dr. Bosch said the “B” was for better, and DocL and I have been saying “+” because Dr. Bosch and many scientist collaborators improved the selection and narrowed manufacturing ranges since that time. Making it far more potent. They also learned how to get some suppressed patient pbmc boosted into fully functioning partially matured DCs.
Interesting. A couple days ago, we received a DCVax-Direct patent granted out to June 2036 in India (1.4 billion people), and Mr. Sarma, who received his undergraduate in India, moved onto our board. Looks like he was one of those young geniuses back in the early computing transitional launch days. Good person to have on the board for multiple reasons.
Your bracket is already broken.
Regardless of trader manipulation, resolution is much closer at hand, with major
hurdles behind us.
🔑Now you’re misleading what the defense incorrectly stated.
Here is what they mistated
….and the new allegations and exhibits across NWBO’s 482-page
pleading (of which 144 pages are entirely new)…
If you are counting exhibit pages as well, you are arguing for the plaintiff, because defendants were mistakingly thinking they had to deal with 482 pages of modified complaint plus exhibits. You are pointing out it’s only 158 combined and limited to one section of the complaint (aka: loss causation). Maybe you should sign on to plaintiff’s schedule, being that you pointed out, combined, it’s three times shorter than defendants suggest.
What’s your point? Those are exhibits supporting the loss causation section. The body of the complaint only changed 17 pages restricted to the loss causation section, and most of those were previously argued?
Why would you say that, those are exhibits supporting the 17 page loss causation section.
🔔New filings. Posner explains the refiling contains the exact same info in exhibit one, as the first amended complaint, and plaintiffs had inadvertently filed the old exhibit 1 copy from the original complaint.
In other words, nothing changed in exhibit one from the first amended complaint to the second amended (resubmitted with intended Exhibit 1 copy) complaint, which the clerk allowed them to refile exhibit one from the first amended complaint in the second amended complaint filing.
Aside from that nonissue, Laura Posner pointed out there are only 17 pages difference in the second amended complaint and all of that is specifically restricted to the loss causation section, and most of it has already been litigated.
In other words, unless the judge likes spring breaks, Defendant’s request for extension should be denied, imo.
I think it’s highly likely NICE had that type of chit chat with NWBO back in 2018, and guess what, NWBO collected five more years data and developed ECA to avoid the inevitable pitfalls of cross-over efficacy.
They stated some of those planned combos are with outside third parties.
Dear Col. Nathan R. Jessup, please quit justifying and encouraging the illegal behavior known as spoofing.
Despite submitting an maa submission just before the first of the year, despite progress with NICE, despite adding a DCVax Direct patent that goes out to June 2036 in a country with 1.5 billion people, the pressure on decreasing PPS accelerated. Despite learning tha NWBO had increased its intellectual property by in licensing. Despite NWBO confirming it plans to proceed with combination trials after it handles maa inspections.
For there to be a contempt finding, after the preliminary injunction was put in place, you’d have to show one (or some small number) significant spoofing violation, imo.